We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
- Authors
Lee, J-L; Ahn, J-H; Choi, M K; Kim, Y; Hong, S-W; Lee, K-H; Jeong, I-G; Song, C; Hong, B-S; Hong, J H; Ahn, H
- Abstract
Background:There has been no previous study on the activity of gemcitabine in combination with oxaliplatin (GemOx) for castration-resistant prostate cancer (CRPC).Methods:The GemOx was preclinically tested for cytotoxic activity in human prostate cancer cell lines. Clinically, patients with CRPC who failed prior docetaxel were treated with gemcitabine 1000 mg m−2 and oxaliplatin 100 mg m−2 intravenously every 2 weeks and prednisolone 5 mg orally twice daily. The primary end point was the prostate-specific antigen (PSA) response rate.Results:The GemOx displayed synergistic effects based on Chou and Talalay analysis. In the phase II study, 33 patients were accrued. The median dose of docetaxel exposure was 518 mg m−2. A total of 270 cycles were administered with a median of eight cycles per patient. A PSA response rate was 55% (95% CI, 38-72) and radiologic response rate was 82% (9 out of 11). With a median follow-up duration of 20.5 months, the median time to PSA progression was 5.8 months (95% CI, 4.4-7.2) and the median overall survival was 17.6 months (95% CI, 12.6-22.6). The most frequently observed grade 3 or 4 toxicities were neutropenia (13%) and thrombocytopenia (13%).Conclusions:The GemOx is active and tolerable in patients with metastatic CRPC after docetaxel failure (NCT 01487720).
- Subjects
OXALIPLATIN; NUCLEOSIDES; CASTRATION; PROSTATE cancer treatment; CANCER relapse; DOCETAXEL; CANCER chemotherapy; CANCER cells
- Publication
British Journal of Cancer, 2014, Vol 110, Issue 10, p2472
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/bjc.2014.204